Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 03.11.2025 1 Am J Surg 5 Ann Surg Oncol 4 Anticancer Res 4 BMC Cancer 8 Breast Cancer 3 Breast Cancer (Dove Med Press) 10 Breast Cancer Res 1 Breast J 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 3 Clin Breast Cancer 1 Clin Cancer Res 1 Clin Exp Metastasis 2 Eur J Cancer 3 Eur Radiol 4 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 1 JAMA 1 Lancet Oncol 1 Mod Pathol 1 N Engl J Med 7 NPJ Breast Cancer 1 Oncol Rep 1 PLoS Biol 1 PLoS Comput Biol 2 PLoS One 1 Proc Natl Acad Sci U S A 2 Radiol Imaging Cancer 1 Radiology 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg

1. CARTWRIGHT SB, Sener SF
   Ongoing debate: Surgical staging of the axilla for invasive breast cancer.
   Am J Surg. 2025;251:116671.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. RANGEL M, Paul S, Gupta D, McPeek C, et al
   Evaluating the Gail Model: Racial Disparities in Breast Cancer Risk Assessment.
   Ann Surg Oncol. 2025 Oct 25. doi: 10.1245/s10434-025-18593.
   PubMed         Abstract available
   
   
3. COX CE, Schumacher J, Lillie M, Carino J, et al
   Simultaneous Omission of Sentinel Lymph Node Biopsy and Radiation in Older Women with Early ER+ Breast Cancer.
   Ann Surg Oncol. 2025 Oct 27. doi: 10.1245/s10434-025-18631.
   PubMed         Abstract available
   
   
4. HAMID SA, Moses J, Lynch OF, Washington R, et al
   ASO Visual Abstract: Financial Outlook thRough CAncer STorytelling (FOReCAST): Development of a Novel Video-Based Storytelling Intervention to Mitigate Financial Hardship Among Young Women with Breast Cancer.
   Ann Surg Oncol. 2025 Oct 27. doi: 10.1245/s10434-025-18585.
   PubMed        
   
   
5. TORTORELLO GN, Shafique N, De Jesus EM, Gimotty P, et al
   Sentinel Lymph Node Biopsy in Low-Risk Breast Cancer in Patients >/= 70 Years: How Wisely are We Choosing?
   Ann Surg Oncol. 2025 Oct 30. doi: 10.1245/s10434-025-18534.
   PubMed         Abstract available
   
   
6. TANG A, Wu PS, Farmah P, Schulz-Costello K, et al
   Omission of Axillary Lymph Node Dissection in Patients with pT0-2 ER+/HER2- Breast Cancer with 3-5 Positive Lymph Nodes Undergoing Adjuvant Systemic Therapy and Radiation Does Not Impact Overall Survival: A National Cancer Database Analysis.
   Ann Surg Oncol. 2025 Oct 24. doi: 10.1245/s10434-025-18546.
   PubMed         Abstract available
   
   

   
   Anticancer Res

7. WOO SH, Lee YH, Jung BC, Kim YS, et al
   Pulsed Electromagnetic Field Promotes Doxorubicin-induced Apoptosis by Increasing Caspase-2 Activation in MDA-MB-231 Breast Cancer Cells.
   Anticancer Res. 2025;45:4921-4931.
   PubMed         Abstract available
   
   
8. YANG M, Han J, Won H, Chae SW, et al
   Automated Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma Using Deep Learning on Pretreatment Core Needle Biopsy Samples.
   Anticancer Res. 2025;45:5167-5176.
   PubMed         Abstract available
   
   
9. HUNG CC, Wang YC, Liu CH, Lin ML, et al
   Impact of Interleukin-12B Genotypes on Breast Cancer Risk.
   Anticancer Res. 2025;45:4771-4781.
   PubMed         Abstract available
   
   
10. ESKELINEN M, Koskela R, Selander T, Kaarniranta K, et al
    An Investigation of Alexithymia Personality Features Versus Outcome: A Prospective 25-year Follow-up Study in Women With Breast Cancer Symptoms.
    Anticancer Res. 2025;45:5085-5094.
    PubMed         Abstract available
    
    

    
    BMC Cancer

11. RE F, Manaboriboon N, Raza IGA, Shipley A, et al
    A systematic review of prediction models for risk of breast cancer.
    BMC Cancer. 2025;25:1650.
    PubMed         Abstract available
    
    
12. TOMCZIK K, Niznik J, Coombs LA
    "Who's gonna take care of my babies?" the impact of children on treatment decisions for women with metastatic breast cancer: a qualitative analysis.
    BMC Cancer. 2025;25:1662.
    PubMed         Abstract available
    
    
13. ZAFAR S, Badshah Y, Shabbir M, Khan S, et al
    Comprehensive computational analysis of PKCdelta non-synonymous variants identifies rs1703863535 as a potential breast cancer biomarker.
    BMC Cancer. 2025;25:1667.
    PubMed         Abstract available
    
    
14. ELSNER SA, Haussmann E, Grieger P, Hadwiger M, et al
    Optimising breast cancer screening in national mammography screening centres: challenges and insights on implementing additional ultrasound for women with dense breast tissue - a qualitative study.
    BMC Cancer. 2025;25:1684.
    PubMed        
    
    

    
    Breast Cancer

15. GUO X, Gong X, Wang L, Xiao H, et al
    Impact of postoperative complications on patient-reported outcomes in deep inferior epigastric perforator flap breast reconstruction.
    Breast Cancer. 2025;32:1318-1325.
    PubMed         Abstract available
    
    
16. AIHARA T, Aritake N, Imamura M, Okishiro M, et al
    Cosmetic outcomes of rotation flap and suture scaffold for breast-conserving therapy in the lower quadrants.
    Breast Cancer. 2025;32:1417-1422.
    PubMed         Abstract available
    
    
17. HARA Y, Yamaguchi R, Otsubo R, Urakawa S, et al
    Macroscopic morphology of breast carcinoma: associations with biological subtypes and pathological features.
    Breast Cancer. 2025;32:1423-1433.
    PubMed         Abstract available
    
    
18. SEKI H, Watanabe N, Nagura N, Ogiya A, et al
    Impact of radiation therapy on breast satisfaction and health-related quality of life after breast reconstruction: a multicenter cross-sectional controlled study (Reborn study-02).
    Breast Cancer. 2025;32:1384-1393.
    PubMed         Abstract available
    
    
19. UEKI Y, Horimoto Y, Harada K, Ushiyama Y, et al
    Breast tumors with intermediate ER expression differ biologically from ER-low tumors and exhibit a more favorable prognosis.
    Breast Cancer. 2025;32:1255-1261.
    PubMed         Abstract available
    
    
20. SEMBA R, Eguchi H, Takatsu M, Hashizume T, et al
    Two-hit events occurred independently in bilateral breast cancers in a germline double heterozygous carrier for BRCA1 and BRCA2.
    Breast Cancer. 2025;32:1472-1479.
    PubMed         Abstract available
    
    
21. MASUYAMA M, Shimoda M, Seto I, Kikumori K, et al
    Targeting focal adhesion kinase inhibits cell migration and non-angiogenic vascularization in malignant breast cancer.
    Breast Cancer. 2025 Oct 28. doi: 10.1007/s12282-025-01792.
    PubMed         Abstract available
    
    
22. KUSAMA H, Takahashi Y, Orihara S, Adachi K, et al
    Evaluating the quality of Japanese YouTube videos on breast cancer treatment using PRHISM: comparison by source credibility.
    Breast Cancer. 2025 Oct 29. doi: 10.1007/s12282-025-01796.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

23. QU X, Wang C, Xu Y, Yang X, et al
    LINC00917 Promotes Bone Metastasis of Breast Cancer by Targeting the miR-491-5p/FOXP4 Axis.
    Breast Cancer (Dove Med Press). 2025;17:913-925.
    PubMed         Abstract available
    
    
24. QIN Y, Chen S, Tao D, Lin Q, et al
    Ambra1 Deficiency Inhibits the Proliferation of Breast Cancer Cells Through the Akt-FoxO1-p27 Pathway.
    Breast Cancer (Dove Med Press). 2025;17:949-965.
    PubMed         Abstract available
    
    
25. ALI A, Alghamdi M, Marzuki SS, Tengku Din TADAA, et al
    Exploring AI Approaches for Breast Cancer Detection and Diagnosis: A Review Article.
    Breast Cancer (Dove Med Press). 2025;17:927-947.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

26. VASSON F, Matta K, Biessy C, S Antoniussen C, et al
    Lifestyle changes and postmenopausal breast cancer risk in women from the European Prospective Investigation into Cancer and Nutrition.
    Breast Cancer Res. 2025;27:192.
    PubMed         Abstract available
    
    
27. CHO Y, Jang Y, Woo HY, Chang Y, et al
    Longitudinal changes in mammographic density and reproductive hormones during the menopausal transition in middle-aged Korean women: effect modification by obesity.
    Breast Cancer Res. 2025;27:193.
    PubMed         Abstract available
    
    
28. KRASNOW NA, Jayaraj M, Salans M, Kuwahara K, et al
    Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study.
    Breast Cancer Res. 2025;27:191.
    PubMed         Abstract available
    
    
29. LIU M, Zou L, Zhang N, Zhou W, et al
    Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial.
    Breast Cancer Res. 2025;27:190.
    PubMed         Abstract available
    
    
30. DAS GUPTA S, Getz K, Hernandez Lopez J, Bennett DL, et al
    Associations of early-adulthood adiposity with breast parenchymal tissue complexity within premenopausal women.
    Breast Cancer Res. 2025;27:188.
    PubMed         Abstract available
    
    
31. DEBINSKI W, Fink KN, Rossmeisl J, Mott RT, et al
    Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate.
    Breast Cancer Res. 2025;27:189.
    PubMed         Abstract available
    
    
32. COLEMAN MF, McDonell SB, Eisenbeis LK, Devericks EN, et al
    The nonsteroidal anti-inflammatory drug sulindac reverses obesity-driven immunosuppression and triple-negative breast cancer progression.
    Breast Cancer Res. 2025;27:186.
    PubMed         Abstract available
    
    
33. FERNANDEZ-MORATA J, Pollan M, Fernandez de Larrea-Baza-Baz N, Pachon-Olmos V, et al
    Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index.
    Breast Cancer Res. 2025;27:187.
    PubMed         Abstract available
    
    
34. SAINI M, Parvar TA, Graham C, Larson NB, et al
    Deep learning-powered multi-parametric ultrasound for classifying metastatic versus reactive axillary lymph nodes.
    Breast Cancer Res. 2025;27:185.
    PubMed         Abstract available
    
    
35. RAVANI VL, Bagheri Z, Brufsky AM, Michelon I, et al
    Correction: Comparative efficacy of first- versus second-line CDK4/6 Inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2025;27:183.
    PubMed        
    
    

    
    Breast J

36. TANG K, Bai S, Zhou Q, Liu S, et al
    MicroRNA-195-5p Targets MYB to Regulate Proliferation and Malignant Metastasis in Triple-Negative Breast Cancer via PI3K/AKT/mTOR Signaling.
    Breast J. 2025;2025:7303173.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

37. OBENG-GYASI S, Handley D, Plascak JJ, Anampa JD, et al
    Neighborhood Contexts and Healthcare Utilization in Patients with Breast Cancer Receiving Chemotherapy.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Cancer Lett

38. KRAWCZYNSKA N, Wang Y, Lim K, Das Gupta A, et al
    Neutrophils exposed to a cholesterol metabolite secrete extracellular vesicles that promote epithelial-mesenchymal transition and stemness in breast cancer cells.
    Cancer Lett. 2025 Oct 28:218105. doi: 10.1016/j.canlet.2025.218105.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

39. TAMM M, Padrik P, Ojamaa K, Paas A, et al
    Clinical Implementation Study of Genetic Risk-Based Breast Cancer Screening.
    Clin Breast Cancer. 2025 Sep 10:S1526-8209(25)00248.
    PubMed         Abstract available
    
    
40. DA SILVA JL, da Silva LFL, Schwengber WK, de Albuquerque LZ, et al
    Evaluating the Efficacy and Safety of NEOadjuvant CHEmoimmunotherapy in Early ER-Low/HER2-Negative Breast Cancer (NEOCHEER): A Systematic Review and Meta-Analysis.
    Clin Breast Cancer. 2025 Oct 3:S1526-8209(25)00286.
    PubMed         Abstract available
    
    
41. PADRAO TG, Pessoa D, Luis JA, Costa DA, et al
    The Use and Impact on Treatment Decision of the 21-Gene Recurrence Score Assay for Patients With HR+/HER2- Early Breast Cancer in Portugal: A Nationwide Retrospective Cohort Study.
    Clin Breast Cancer. 2025 Sep 23:S1526-8209(25)00282.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

42. BROWNE IM, Pascual J, Cutts RJ, Kingston B, et al
    The Prognostic and Predictive Impact of Circulating Tumour DNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial.
    Clin Cancer Res. 2025 Oct 29. doi: 10.1158/1078-0432.CCR-24-0651.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

43. BENDRICH S, Pietrkiewicz MAW, Schirmer MA, Ammon HE, et al
    Borderline decisions in brain-metastatic breast cancer: efficacy of multimodality treatments in breast cancer patients with very limited prognosis suffering from brain metastases.
    Clin Exp Metastasis. 2025;42:62.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

44. SPOOR DS, Boekel NB, Leeuwen FEV, Russell N, et al
    Predicting acute coronary events after breast cancer radiotherapy: Integrating baseline cardiovascular risk, systemic therapy, and cardiac radiation dose in the MEDIRAD BRACE study.
    Eur J Cancer. 2025;231:116055.
    PubMed         Abstract available
    
    
45. BELCASTRO E, Marletta S, Tornabene I, Cinacchi P, et al
    MTClin: Integrating MammaTyper(R) to predict neoadjuvant therapy response in HER2+?breast cancer.
    Eur J Cancer. 2025;230:116049.
    PubMed         Abstract available
    
    

    
    Eur Radiol

46. GATEWOOD J, Peterson J, Aripoli A, Huppe A, et al
    Can a low b-value diffusion-weighted imaging sequence replace the standard T2-weighted fluid-sensitive sequence in breast MRI? A single-center prospective study.
    Eur Radiol. 2025;35:7235-7243.
    PubMed         Abstract available
    
    
47. SEKER ME, Ozkan O
    Navigating the future of mammography triaging: insights from combined usage of AI algorithms in breast cancer screening.
    Eur Radiol. 2025 Oct 24. doi: 10.1007/s00330-025-12095.
    PubMed        
    
    
48. XU Z, Zhang Y, Zou Y, He Y, et al
    Identify high-risk patients of T1-2N1M0 breast cancer who benefit from postmastectomy radiotherapy: a dual-center retrospective propensity score-matched study.
    Eur Radiol. 2025 Oct 25. doi: 10.1007/s00330-025-12091.
    PubMed         Abstract available
    
    

    
    Int J Cancer

49. DANIELSSON O, Dar H, Perez-Tenorio G, Nordenskjold A, et al
    Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.
    Int J Cancer. 2025 Oct 24. doi: 10.1002/ijc.70209.
    PubMed         Abstract available
    
    
50. OTT LF, Keller L, Bentley N, Husseini-Wusthoff H, et al
    Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane.
    Int J Cancer. 2025 Oct 27. doi: 10.1002/ijc.70216.
    PubMed         Abstract available
    
    
51. TUNBEKICI S, Sahin G, On S, Oruc A, et al
    Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.
    Int J Cancer. 2025 Oct 28. doi: 10.1002/ijc.70213.
    PubMed         Abstract available
    
    
52. HLEVNJAK M, Heublein S, Thewes V, Wagener L, et al
    Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experience.
    Int J Cancer. 2025 Oct 31. doi: 10.1002/ijc.70208.
    PubMed         Abstract available
    
    

    
    Int J Oncol

53. MALLA RR, Raghu H, Rao JS
    [Expression of Concern] Regulation of NADPH oxidase (Nox2) by lipid rafts in breast carcinoma cells.
    Int J Oncol. 2026;68:1.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

54. FACONDO G, Reverberi C, Prisco A, Ceschia T, et al
    Post-Operative Single Fraction Stereotactic Partial Breast Irradiation (S-PBI) for Early-Stage Breast Cancer with Gammapod Technology: A Phase II Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2025 Oct 27:S0360-3016(25)06400.
    PubMed         Abstract available
    
    

    
    JAMA

55. PANT S
    Lesser-Known Lobular Breast Cancer on the Rise.
    JAMA. 2025 Oct 24. doi: 10.1001/jama.2025.17524.
    PubMed        
    
    

    
    Lancet Oncol

56. BARTSCH R, Marhold M, Garde-Noguera J, Gion M, et al
    Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2025;26:1467-1478.
    PubMed         Abstract available
    
    

    
    Mod Pathol

57. RAKHA EA, Tan PH, Van Bockstal MR, Allison KH, et al
    International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-low and Ultralow Categories.
    Mod Pathol. 2025 Oct 28:100925. doi: 10.1016/j.modpat.2025.100925.
    PubMed         Abstract available
    
    

    
    N Engl J Med

58. TOLANEY SM, Jiang Z, Zhang Q, Barroso-Sousa R, et al
    Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
    N Engl J Med. 2025 Oct 29. doi: 10.1056/NEJMoa2508668.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

59. FERGUS KB, Newberg J, Greenstein R, Fejerman L, et al
    Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer.
    NPJ Breast Cancer. 2025;11:117.
    PubMed         Abstract available
    
    
60. WANG X, Tan T, Gao Y, Su R, et al
    Predicting short- to long-term breast cancer risk from longitudinal mammographic screening history.
    NPJ Breast Cancer. 2025;11:118.
    PubMed         Abstract available
    
    
61. WAHNER HENDRICKSON AE, Flatten KS, Weiskittel TM, Venkatachalam A, et al
    CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
    NPJ Breast Cancer. 2025;11:112.
    PubMed         Abstract available
    
    
62. TAKADA M, Saji S, Ueno T, Masuda N, et al
    Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey.
    NPJ Breast Cancer. 2025;11:113.
    PubMed         Abstract available
    
    
63. DHARA A, Aier I, Das S, Sarkar M, et al
    Enhanced ETS1 stability by DNAPKcs orchestrates transcriptional changes during chemoresistance in triple negative breast cancer.
    NPJ Breast Cancer. 2025;11:114.
    PubMed         Abstract available
    
    
64. POTTER S, Avery K, Ahmed R, de Boniface J, et al
    A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials.
    NPJ Breast Cancer. 2025;11:116.
    PubMed         Abstract available
    
    
65. BHIMANI J, O'Connell K, Gallagher GB, Blinder VS, et al
    Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer.
    NPJ Breast Cancer. 2025;11:119.
    PubMed         Abstract available
    
    

    
    Oncol Rep

66. MATSUNUMA R, Kinoshita K, Imada S, Sato S, et al
    CD44 knockdown and TGF?beta inhibition modulate cell proliferation and invasion in claudin?low breast cancer cells.
    Oncol Rep. 2026;55:7.
    PubMed         Abstract available
    
    

    
    PLoS Biol

67. MUTNURU SA, Yadav P, Kakani P, Dhamdhere SG, et al
    PRMT5 regulates alternative splicing of TCF3 under hypoxia to promote EMT and invasion in breast cancer.
    PLoS Biol. 2025;23:e3003444.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

68. MATACHE A, Lima-Junior JR, Kuznetsov M, Urbaniak K, et al
    Ligand discrimination in immune cells: Signal processing insights into immune dysfunction in ER+ breast cancer.
    PLoS Comput Biol. 2025;21:e1013615.
    PubMed         Abstract available
    
    

    
    PLoS One

69. LIU J, Liu J, Wang M, Wang X, et al
    Opioid-sparing anesthesia versus opioid-free anesthesia for postoperative recovery quality in breast cancer surgery patients: A systematic review and Bayesian network meta-analysis.
    PLoS One. 2025;20:e0334614.
    PubMed         Abstract available
    
    
70. AHMADI M, Nemat A, Sakhi R, Ahmadi A, et al
    Knowledge and practice of breast self-examination and associated factors among women with breast cancer in Kabul, Afghanistan.
    PLoS One. 2025;20:e0335460.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

71. AYLON Y, Furth N, Pirona AC, Lavie A, et al
    p53 regulates the expression of histone modifiers to restrict stemness and maintain differentiated luminal identity in breast cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2522646122.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

72. MILES RC, Walsh CJ, Tran NT, Garcia J, et al
    Sociodemographic Predictors of County-Level Mammography Screening Rates in the United States.
    Radiol Imaging Cancer. 2025;7:e240433.
    PubMed         Abstract available
    
    
73. TEKCAN SANLI DE, Sanli AN
    Outcomes in Symptomatic and Screen-detected Breast Cancer: Age, Tumor Biology, and Study Design Matter.
    Radiol Imaging Cancer. 2025;7:e250395.
    PubMed        
    
    

    
    Radiology

74. ROTHWELL JWD, Rogers P, Payne NR, Huang Y, et al
    Evaluation of a Mammography-based Deep Learning Model for Breast Cancer Risk Prediction in a Triennial Screening Program.
    Radiology. 2025;317:e250391.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

75. ZAMAGNI A, Luis AM, Mjaaland I, Chirila ME, et al
    ESTRO recommendations on preoperative radiation therapy in breast cancer: current and future perspectives.
    Radiother Oncol. 2025 Oct 27:111236. doi: 10.1016/j.radonc.2025.111236.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.